How Psychedelic Medicine Could Change Chronic Pain Relief
Las Vegas, Tuesday, 15 September 2026.
Ensysce Biosciences presented novel psychedelic-based treatments for chronic pain and advocated for clear regulatory frameworks during a landmark FDA hearing on non-opioid medical therapies.
Symposium Presentations and Clinical Updates
On September 15, 2026, Ensysce Biosciences, Inc. (NASDAQ: ENSC) detailed its progress in pain management therapeutics during a symposium at PainWeek 2026 [1][2]. The event gathered over 320 pain management professionals to review the company’s Complex Regional Pain Syndrome Type 1 (CRPS) development program [1][2]. Dr. Jeff Gudin presented updates on the safer opioid program and CRPS initiatives, while Dr. Richard Langford discussed the neuroplastogenic therapy platform acquired from Cy Biopharma [1][2]. This acquisition expands the company’s pipeline to include central nervous system modulation treatments designed to address chronic pain conditions [1][2]. The clinical-stage biotechnology company continues to focus on developing abuse-deterrent and overdose-resistant opioid candidates alongside these novel neuroplastogenic therapies [1][2].
Regulatory Engagement and FDA Hearing
Following the symposium, company representatives participated in a United States Food and Drug Administration (FDA) hearing concerning the regulatory framework for psychedelic-based medicines [1][2]. The discussion focused on credentialing, safety data collection, and access protocols for these emerging treatments [1][2]. Lynn Kirkpatrick, Ph.D., Chief Executive Officer of Ensysce Biosciences, noted that the hearing provided a substantial voice for public understanding regarding the use and training associated with psychedelic-based medicines [1][2]. Dr. Langford specifically addressed considerations for access and best practices for data standardization, advocating for the role of interventional pain physicians in drug delivery [1][2]. Feedback was gathered from healthcare providers and patients across the United States, Canada, and Mexico, as well as from states with established clinical psychedelic programs [1][2].
Strategic Outlook and Risk Factors
Ensysce Biosciences aims to advance its neuroplastogenic therapies and implement a Phase 2 clinical trial, though specific dates for these milestones were not disclosed as of September 14, 2026 [1][2]. The company’s forward-looking statements are subject to significant risks defined under The Private Securities Litigation Reform Act of 1995, including potential Nasdaq delisting and challenges in obtaining stockholder approval for Series C non-voting convertible preferred stock conversion [1][2]. Capital sufficiency remains a primary concern, with advancement contingent upon obtaining sufficient funding, including potential government support [1][2]. Ensysce Biosciences maintains reporting obligations under U.S. Securities and Exchange Commission (SEC) filings, specifically referencing Form 10-K and Form 10-Q documentation for primary risk disclosures [1][2].